Transcatheter Valve Data Gets Top-Line Attention At EuroPCR
This article was originally published in The Gray Sheet
Data from multiple registries presented last week at the EuroPCR conference in Paris offered no major trouble spots for European cardiologists looking to expand use of transcatheter aortic heart valves and U.S. doctors anxiously awaiting their approval
You may also be interested in...
Data from the first-ever randomized trial of a transcatheter aortic heart valve show a substantial one-year survival benefit for Edwards Lifesciences' Sapien versus standard medical therapy, giving the firm major momentum as it prepares to submit one of two upcoming PMAs for the device